Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain.

A peculiar point mutation results in constitutive activation of c-kit receptor tyrosine kinase (KIT) in three different tumor mast cell lines; ie, the HMC-1, P-815, and RBL-2H3. Because constitutive activation of KIT was also observed in the FMA3 mouse mastocytoma cell line, we investigated the molecular mechanism. Sequencing of the whole coding region of the c-kit showed that the point mutation found in HMC-1, P-815, and RBL-2H3 cells was absent in FMA3 cells and that the c-kit cDNA of FMA3 cells carried an in-frame deletion of 21 base pairs (bp) encoding Thr-Gln-Leu-Pro-Tyr-Asp-His at codons 573 to 579 at the juxtamembrane domain. The FMA3-type c-kit cDNA with 21 bp deletion was introduced into the IC-2 cell line, which was derived from murine cultured mast cells. IC-2 cells were dependent on interleukin (IL)-3 and did not express KIT on the surface. In IC-2 cells introduced with the FMA3-type c-kit cDNA, KIT was constitutively phosphorylated on tyrosines and activated. Moreover, the FMA3-type KIT was dimerized without the stimulation by stem cell factor (SCF), a ligand for KIT. The spontaneously dimerized FMA3-type KIT without SCF binding was not internalized even after the activation. IC-2 cells expressing the FMA3-type KIT grew in suspension culture without IL-3 and SCF and became leukemic in nude athymic mice. The deletion of seven amino acids at the juxtamembrane domain appeared to be a new activating mutation of KIT that might be involved in neoplastic growth of mast cells.

[1]  Y. Matsuzawa,et al.  Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3. , 1995, International archives of allergy and immunology.

[2]  H. Kitayama,et al.  Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. , 1995, Blood.

[3]  al. et,et al.  Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B , 1995, Science.

[4]  A. Ullrich,et al.  Oncogenic activation of v-kit involves deletion of a putative tyrosine-substrate interaction site. , 1995, Oncogene.

[5]  W. Muller,et al.  Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. , 1994, Molecular and Cellular Biology.

[6]  L. Rohrschneider,et al.  Tyrosine 569 in the c-Fms juxtamembrane domain is essential for kinase activity and macrophage colony-stimulating factor-dependent internalization , 1994, Molecular and cellular biology.

[7]  Y. Matsuzawa,et al.  Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation , 1994 .

[8]  H. Serve,et al.  Tyrosine residue 719 of the c-kit receptor is essential for binding of the P85 subunit of phosphatidylinositol (PI) 3-kinase and for c-kit-associated PI 3-kinase activity in COS-1 cells. , 1994, The Journal of biological chemistry.

[9]  R. Hofstra,et al.  A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma , 1994, Nature.

[10]  T. Kubota,et al.  Sequence of a bovine c-kit proto-oncogene cDNA. , 1994, Gene.

[11]  Y. Matsuzawa,et al.  Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation. , 1994, Blood.

[12]  L. Ashman,et al.  Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. , 1993, The Journal of clinical investigation.

[13]  B. Ponder,et al.  Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A , 1993, Nature.

[14]  J. Ihle,et al.  Association of hematopoietic cell phosphatase with c-Kit after stimulation with c-Kit ligand , 1993, Molecular and cellular biology.

[15]  Y. Nishimune,et al.  Mast cell number in the skin of heterozygotes reflects the molecular nature of c-kit mutation. , 1993, Blood.

[16]  C. Michnoff,et al.  Multiple B29 containing complexes on murine B lymphocytes. Common and stage-restricted Ig-associated polypeptide chains. , 1993, Journal of immunology.

[17]  W. Fantl,et al.  Signalling by receptor tyrosine kinases. , 1993, Annual review of biochemistry.

[18]  M. Naito,et al.  Cloning and expression of the chicken c-kit proto-oncogene. , 1993, Gene.

[19]  L. Larue,et al.  Spontaneous malignant transformation of melanocytes explanted from Wf/Wf mice with a Kit kinase-domain mutation. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[20]  C. Fitzer-Attas,et al.  Mouse platelet-derived growth factor alpha receptor: sequence, tissue-specific expression and correlation with metastatic phenotype. , 1992, Oncogene.

[21]  Y. Yarden,et al.  Structural organization of the murine c-kit proto-oncogene. , 1992, Oncogene.

[22]  S. Lev,et al.  Interkinase domain of kit contains the binding site for phosphatidylinositol 3' kinase. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[23]  C. Heldin,et al.  Activation of the human c‐kit product by ligand‐induced dimerization mediates circular actin reorganization and chemotaxis. , 1991, The EMBO journal.

[24]  H. Kitayama,et al.  Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. , 1991, Blood.

[25]  E. Morii,et al.  Characterization of Ws mutant allele of rats: a 12-base deletion in tyrosine kinase domain of c-kit gene. , 1991, Blood.

[26]  Alastair,et al.  Signal transduction by normal isoforms and W mutant variants of the Kit receptor tyrosine kinase. , 1991, The EMBO journal.

[27]  T. Pawson,et al.  The Steel/W transduction pathway: kit autophosphorylation and its association with a unique subset of cytoplasmic signaling proteins is induced by the Steel factor , 1991, Molecular and cellular biology.

[28]  K. Davies,et al.  Molecular biology of the W and steel loci. , 1991 .

[29]  H. Kitayama,et al.  Proliferation of human myeloid leukemia cell line associated with the tyrosine-phosphorylation and activation of the proto-oncogene c-kit product. , 1991, Blood.

[30]  P. Leder,et al.  The hematopoietic growth factor KL is encoded by the SI locus and is the ligand of the c-kit receptor, the gene product of the W locus , 1990, Cell.

[31]  David A. Williams,et al.  Stem cell factor is encoded at the SI locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor , 1990, Cell.

[32]  N. Copeland,et al.  Mast cell growth factor maps near the steel locus on mouse chromosome 10 and is deleted in a number of steel alleles , 1990, Cell.

[33]  P. Leder,et al.  The kit ligand: A cell surface molecule altered in steel mutant fibroblasts , 1990, Cell.

[34]  C. March,et al.  Identification of a ligand for the c-kit proto-oncogene , 1990, Cell.

[35]  S. Cannistra,et al.  Signal transduction of the human granulocyte-macrophage colony-stimulating factor and interleukin-3 receptors involves tyrosine phosphorylation of a common set of cytoplasmic proteins. , 1990, Blood.

[36]  K. Nocka,et al.  Molecular bases of dominant negative and loss of function mutations at the murine c‐kit/white spotting locus: W37, Wv, W41 and W. , 1990, The EMBO journal.

[37]  Joseph Schlessinger,et al.  Signal transduction by receptors with tyrosine kinase activity , 1990, Cell.

[38]  A. Reith,et al.  W mutant mice with mild or severe developmental defects contain distinct point mutations in the kinase domain of the c-kit receptor. , 1990, Genes & development.

[39]  L. Rohrschneider,et al.  Activation of the feline c-fms proto-oncogene: Multiple alterations are required to generate a fully transformed phenotype , 1988, Cell.

[40]  J. Downing,et al.  A point mutation in the extracellular domain of the human CSF-1 receptor (c-fms proto-oncogene product) activates its transforming potential , 1988, Cell.

[41]  S. Majumder,et al.  c-kit protein, a transmembrane kinase: identification in tissues and characterization , 1988, Molecular and cellular biology.

[42]  D. Housman,et al.  The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene , 1988, Cell.

[43]  V. Chapman,et al.  The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus , 1988, Nature.

[44]  Cori Bargmann,et al.  Oncogenic activation of the neu‐encoded receptor protein by point mutation and deletion. , 1988, The EMBO journal.

[45]  F. Ruddle,et al.  Primary structure of c‐kit: relationship with the CSF‐1/PDGF receptor kinase family–oncogenic activation of v‐kit involves deletion of extracellular domain and C terminus. , 1988, The EMBO journal.

[46]  C. Stocking,et al.  Autocrine stimulation after transfer of the granulocyte/macrophage colony-stimulating factor gene and autonomous growth are distinct but interdependent steps in the oncogenic pathway. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[47]  A. Ullrich,et al.  Human proto‐oncogene c‐kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. , 1987, The EMBO journal.

[48]  M. Roussel,et al.  Transforming potential of the c-fms proto-oncogene (CSF-1 receptor) , 1987, Nature.

[49]  L. Rohrschneider,et al.  Murine c-fms cDNA: cloning, sequence analysis and retroviral expression. , 1987, Oncogene research.

[50]  Cori Bargmann,et al.  Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185 , 1986, Cell.

[51]  John E. Murphy,et al.  A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family , 1986, Nature.

[52]  S. Galli,et al.  Fate of bone marrow-derived cultured mast cells after intracutaneous, intraperitoneal, and intravenous transfer into genetically mast cell- deficient W/Wv mice. Evidence that cultured mast cells can give rise to both connective tissue type and mucosal mast cells , 1985, The Journal of experimental medicine.

[53]  Mary Anne Wheeler,et al.  Stem , 1985 .

[54]  S. Hosoda,et al.  COMPARISON OF SEROTONIN-PRODUCING MURINE MASTOCYTOMAS, P-815 AND FMA3: DETERMINATION OF TRYPTOPHAN HYDROXYLASE, AROMATIC L-AMINO ACID DECARBOXYLASE, AND CELLULAR CONCENTRATION OF TRYPTOPHAN, 5-HYDROXYTRYPTOPHAN, 5-HYDROXYTRYPTAMINE AND 5-HYDROXYINDOLEACETIC ACID , 1984 .

[55]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[56]  D. Baltimore,et al.  Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus , 1983, Cell.

[57]  P Berg,et al.  Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter. , 1982, Journal of molecular and applied genetics.

[58]  Makio,et al.  Clonal assay of mouse mast cell colonies in methylcellulose culture. , 1982, Blood.

[59]  C. Auffray,et al.  Purification of mouse immunoglobulin heavy-chain messenger RNAs from total myeloma tumor RNA. , 2005, European journal of biochemistry.

[60]  M. Wigler,et al.  DNA-mediated transfer of the adenine phosphoribosyltransferase locus into mammalian cells. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[61]  E. Russell Hereditary anemias of the mouse: a review for geneticists. , 1979, Advances in genetics.

[62]  F. Sanger,et al.  DNA sequencing with chain-terminating inhibitors. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[63]  F. Graham,et al.  Characteristics of a human cell line transformed by DNA from human adenovirus type 5. , 1977, The Journal of general virology.

[64]  J. Furth,et al.  Transplantable Mastocytoma in the Mouse Containing Histamine, Heparin, 5-Hydroxytryptamine.∗ , 1957, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.